Becton, Dickinson and Company BDX
213.81 USD -1.44 (-0.67%)
Nov 10, 2026, 9:32 AM EST
213.38 Day range 213.87
140.71 52-week range 215.25
- YTD
- +40.14%
- 1 year
- +49.72%
News
benzinga.com Citigroup Maintains Buy on Becton Dickinson, Raises Price Target to $241 Citigroup analyst Joanna Wiensch maintains Becton Dickinson (NYSE:BDX) with a Buy and raises the price target from $208 to $241.
benzinga.com RBC Capital Maintains Sector Perform on Becton Dickinson, Raises Price Target to $225 RBC Capital analyst Kendall Au maintains Becton Dickinson (NYSE:BDX) with a Sector Perform and raises the price target from $190 to $225.- benzinga.com Evercore ISI Group Maintains Outperform on Becton Dickinson, Raises Price Target to $230 Evercore ISI Group analyst Vijay Kumar maintains Becton Dickinson (NYSE:BDX) with a Outperform and raises the price target from $210 to $230.
zacks.com 3 Stocks in Focus That Hiked Dividends Amid Ongoing Market Volatility BDX, COR and UNF recently hiked dividends, offering investors steady income opportunities as market volatility, inflation and economic uncertainty persist.
benzinga.com Piper Sandler Maintains Neutral on Becton Dickinson, Raises Price Target to $200 Piper Sandler analyst Jason Bednar maintains Becton Dickinson (NYSE:BDX) with a Neutral and raises the price target from $175 to $200.
benzinga.com This Centrus Energy Analyst Turns Bullish; Here Are Top 5 Upgrades For Friday Analysts upgraded Centrus Energy, SiTime, MGE Energy, Steven Madden and Becton Dickinson, with new or higher price targets.
benzinga.com Wells Fargo Upgrades Becton Dickinson to Overweight, Raises Price Target to $242 Wells Fargo analyst Lawrence Biegelsen upgrades Becton Dickinson (NYSE:BDX) from Equal-Weight to Overweight and raises the price target from $170 to $242.
marketbeat.com Becton, Dickinson and Company Q4 Earnings Call Highlights Becton, Dickinson and Company NYSE: BDX reported higher fiscal fourth-quarter revenue and adjusted earnings as demand for patient monitoring, biologic drug delivery and other products helped offset a…
benzinga.com Becton Dickinson Enters Fiscal 2027 With More Focused Portfolio for Sustainable Growth Becton Dickinson beats Q4 earnings and revenue estimates, raises its dividend 1%, authorizes more share buybacks and issues fiscal 2027 profit guidance.
zacks.com Becton Dickinson (BDX) Surpasses Q4 Earnings and Revenue Estimates Becton Dickinson (BDX) came out with quarterly earnings of $4.15 per share, beating the Zacks Consensus Estimate of $4.06 per share. This compares to earnings of $3.96 per share a year ago.
benzinga.com Becton Dickinson Q4 2026 Earnings Call Transcript Becton Dickinson (NYSE:BDX) reported fourth-quarter financial results on Thursday. The transcript from the company’s fourth-quarter earnings call has been provided below.This transcript is brought to…
prnewswire.com BD Reports Fourth Quarter and Full Year Fiscal 2026 Financial Results Q4 revenue of $5.3 billion increased 5.4% as reported, 5.6% FXN Q4 GAAP and adjusted diluted EPS of $2.52 and $4.15, respectively FY26 revenue of $19.5 billion increased 4.9% as reported, 3.9% FXN…
benzinga.com Becton Dickinson Increases Its Quarterly Dividend From $1.05 To $1.06; Will Repurchase Up To 10M Shares In Addition To Those Remaining Under Its Previous 2026 Authorization The dividend will be payable on December 31, 2026 to holders of record on December 10, 2026. The indicated annual dividend rate is $4.24 per share.The board has also authorized the company to…
prnewswire.com BD Board Increases Dividend for 55th Consecutive Year, Authorizes 10 Million Additional Share Repurchases FRANKLIN LAKES, N.J., Nov. 5, 2026 /PRNewswire/ -- The Board of Directors of BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, has declared a quarterly…
benzinga.com Toyota, ConocoPhillips On Deck Thursday As Auto Demand, Oil Prices Face Test Toyota Motor headlines Thursday’s reports, with investors weighing the automaker’s earnings outlook against a stock still well below its 52-week high. ConocoPhillips, Sony Group, Parker Hannifin and…
prnewswire.com BD Names Bridget Bagnato Worldwide President of Peripheral Intervention FRANKLIN LAKES, N.J., Nov. 4, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that Bridget Bagnato has been appointed…
zacks.com BDX Gears Up to Report Q4 Results: How to Play the Stock? BD heads into Q4 earnings with expectations of higher profits despite lower revenues, backed by strength in Interventional, Medical Essentials and Biologics.
zacks.com Becton Dickinson (BDX) Q4 Earnings Preview: What You Should Know Beyond the Headline Estimates Besides Wall Street's top-and-bottom-line estimates for Becton Dickinson (BDX), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared…
benzinga.com Barclays Initiates Coverage On Becton Dickinson with Underweight Rating, Announces Price Target of $165 Barclays analyst Christopher Pasquale initiates coverage on Becton Dickinson (NYSE:BDX) with a Underweight rating and announces Price Target of $165.
benzinga.com Becton Dickinson Commits Massive $19 Billion To Expand Domestic Medical Manufacturing Becton Dickinson announced a $19 billion investment in US manufacturing to secure the healthcare supply chain and achieve tariff relief.
benzinga.com Trump Says Becton Dickinson to Invest $3 Billion in US Manufacturing as 'Strong' Medical Device Tariffs Loom by Year-End Trump says Becton Dickinson will invest $3 Billion in U.S. medical manufacturing as medical-device tariffs are set for year-end.
benzinga.com Becton Dickinson Q3 2026 Earnings Call: Complete Transcript Becton Dickinson (NYSE:BDX) held its third-quarter earnings conference call on Thursday. Below is the complete transcript from the call. This content is powered by Benzinga APIs. For comprehensive…- benzinga.com B of A Securities Maintains Neutral on Becton Dickinson, Raises Price Target to $200 B of A Securities analyst Travis Steed maintains Becton Dickinson (NYSE:BDX) with a Neutral and raises the price target from $185 to $200.
benzinga.com What's Going On With Becton Dickinson Stock Wednesday? FDA alerts Becton Dickinson customers to remove recalled Huons sodium chloride ampules from convenience kits. No injuries reported.
benzinga.com Medline Convenience Kits Impacted By Contamination In Recalled Becton Dickinson Products FDA alerts providers as Medline corrects convenience kits with recalled BD applicators due to sterility and contamination risks.
benzinga.com RBC Capital Maintains Sector Perform on Becton Dickinson, Raises Price Target to $190 RBC Capital analyst Kendall Au maintains Becton Dickinson (NYSE:BDX) with a Sector Perform and raises the price target from $180 to $190.- benzinga.com Becton, Dickinson And Co. Completes Enrollment In PREVENT Clinical Trial Evaluating Phasix Mesh For Prevention Of Incisional Hernias Enrollment completed in the first large-scale randomized study evaluating Phasix™ Mesh for incisional hernia prevention, a significant unmet need following abdominal surgeryFRANKLIN LAKES, N.J., Aug.…
- benzinga.com Citigroup Maintains Buy on Becton Dickinson, Raises Price Target to $204 Citigroup analyst Joanna Wiensch maintains Becton Dickinson (NYSE:BDX) with a Buy and raises the price target from $198 to $204.
- benzinga.com RBC Capital Maintains Sector Perform on Becton Dickinson, Raises Price Target to $180 RBC Capital analyst Kendall Au maintains Becton Dickinson (NYSE:BDX) with a Sector Perform and raises the price target from $175 to $180.
- benzinga.com Piper Sandler Maintains Neutral on Becton Dickinson, Raises Price Target to $175 Piper Sandler analyst Jason Bednar maintains Becton Dickinson (NYSE:BDX) with a Neutral and raises the price target from $161 to $175.
- benzinga.com Wells Fargo Maintains Equal-Weight on Becton Dickinson, Raises Price Target to $170 Wells Fargo analyst Lawrence Biegelsen maintains Becton Dickinson (NYSE:BDX) with a Equal-Weight and raises the price target from $161 to $170.
benzinga.com Becton Dickinson Signals Strong Growth Momentum By Raising Profit Outlook Becton Dickinson raises 2026 adjusted EPS guidance after reporting Q3 revenue growth across core medical and interventional business segments.- benzinga.com Becton, Dickinson Q3 Adj. EPS $3.23 Beats $3.14 Estimate, Sales $4.983B Beat $4.887B Estimate Becton, Dickinson (NYSE:BDX) reported quarterly earnings of $3.23 per share which beat the analyst consensus estimate of $3.14 by 2.87 percent. This is a 12.23 percent decrease over earnings of $3.68…
- benzinga.com Becton Dickinson Raises FY2026 Adj EPS Guidance from $12.52-$12.72 to $12.62-$12.72 vs $12.61 Est Becton Dickinson (NYSE:BDX) raises FY2026 Adj EPS guidance from $12.52-$12.72 to $12.62-$12.72 vs $12.61 analyst estimate..
benzinga.com TD Cowen Maintains Hold on Becton Dickinson, Raises Price Target to $182 TD Cowen analyst Joshua Jennings maintains Becton Dickinson (NYSE:BDX) with a Hold and raises the price target from $163 to $182.- benzinga.com UBS Initiates Coverage On Becton Dickinson with Buy Rating, Announces Price Target of $190 UBS analyst Patrick Wood initiates coverage on Becton Dickinson (NYSE:BDX) with a Buy rating and announces Price Target of $190.
- benzinga.com Evercore ISI Group Maintains Outperform on Becton Dickinson, Lowers Price Target to $180 Evercore ISI Group analyst Vijay Kumar maintains Becton Dickinson (NYSE:BDX) with a Outperform and lowers the price target from $190 to $180.
benzinga.com Becton Dickinson's CentroVena One Insertion System Awarded Innovative Technology Contract From Vizient; Terms Not Disclosed The contract was awarded following a review by hospital experts serving on Vizient's client-led councils, and recognizes that CentroVena One™ offers differentiated capabilities through its all-in-one…
benzinga.com 10 Health Care Stocks Whale Activity In Today's Session - benzinga.com Barclays Maintains Overweight on Becton Dickinson, Raises Price Target to $204 Barclays analyst Matt Miksic maintains Becton Dickinson (NYSE:BDX) with a Overweight and raises the price target from $202 to $204.
- benzinga.com Wells Fargo Maintains Equal-Weight on Becton Dickinson, Raises Price Target to $161 Wells Fargo analyst Lawrence Biegelsen maintains Becton Dickinson (NYSE:BDX) with a Equal-Weight and raises the price target from $157 to $161.
benzinga.com Becton Dickinson Hikes Profit Outlook, Names CFO Becton Dickinson (NYSE: BDX) tops Q2 estimates with $4.71B revenue and raises 2026 earnings outlook. New CFO Vitor Roque appointed.- benzinga.com Becton Dickinson Raises FY2026 Adj EPS Guidance from $12.35-$12.65 to $12.52-$12.72 vs $12.48 Est Becton Dickinson (NYSE:BDX) raises FY2026 Adj EPS guidance from $12.35-$12.65 to $12.52-$12.72 vs $12.48 analyst estimate..
- benzinga.com Becton, Dickinson Q2 Adj. EPS $2.90 Beats $2.77 Estimate, Sales $4.714B Beat $4.673B Estimate Becton, Dickinson (NYSE:BDX) reported quarterly earnings of $2.90 per share which beat the analyst consensus estimate of $2.77 by 4.32 percent. This is a 3.94 percent increase over earnings of $2.79…
benzinga.com BD Announces Strategic Partnership With Wellstar Health System To Enhance Safety And Quality Of Medication Delivery For Patients Across Its Hospitals And Care Facilities By integrating the BD Pyxis™ Pro and BD Alaris™ platforms, Wellstar Health System is giving clinicians clearer insight, greater accuracy and simple automation, so they can focus on delivering safer,…- benzinga.com TD Cowen Maintains Hold on Becton Dickinson, Lowers Price Target to $163 TD Cowen analyst Joshua Jennings maintains Becton Dickinson (NYSE:BDX) with a Hold and lowers the price target from $189 to $163.
- benzinga.com Piper Sandler Maintains Neutral on Becton Dickinson, Lowers Price Target to $159 Piper Sandler analyst Jason Bednar maintains Becton Dickinson (NYSE:BDX) with a Neutral and lowers the price target from $170 to $159.
- benzinga.com Goldman Sachs Reinstates Neutral on Becton Dickinson, Announces $167 Price Target Goldman Sachs analyst David Roman reinstates Becton Dickinson (NYSE:BDX) with a Neutral and announces $167 price target.
- benzinga.com BD Announces Application Of CE Mark For Liverty TIPS Stent Graft, Delivering Innovation To Portal Hypertension Care Across European Union CE Marking and ARCH clinical trial data position the Liverty™ TIPS Stent Graft to expand treatment options for patients with advanced liver diseaseFRANKLIN LAKES, N.J., April 8, 2026 /PRNewswire/ --…
- benzinga.com Argus Research Maintains Buy on Becton Dickinson, Lowers Price Target to $180 Argus Research analyst David Toung maintains Becton Dickinson (NYSE:BDX) with a Buy and lowers the price target from $230 to $180.